Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Mycobacterial trehalose 6,6'-dimycolate preferentially induces type 1 helper T cell responses through signal transducer and activator of transcription 4 protein.

Oiso R, Fujiwara N, Yamagami H, Maeda S, Matsumoto S, Nakamura S, Oshitani N, Matsumoto T, Arakawa T, Kobayashi K.

Microb Pathog. 2005 Jul-Aug;39(1-2):35-43.

PMID:
15967629
2.

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.

Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, Mayner RE, Thole J, Walker KB, Liu M, Lambert PH; AERAS Global TB Vaccine Foundation; World Health Organization.

Vaccine. 2005 May 31;23(29):3753-61. Epub 2005 Mar 24. Review.

PMID:
15893612
3.
4.

Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro.

Downing KJ, Mischenko VV, Shleeva MO, Young DI, Young M, Kaprelyants AS, Apt AS, Mizrahi V.

Infect Immun. 2005 May;73(5):3038-43.

5.

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.

Majlessi L, Brodin P, Brosch R, Rojas MJ, Khun H, Huerre M, Cole ST, Leclerc C.

J Immunol. 2005 Mar 15;174(6):3570-9.

6.

The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses.

Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J.

Eur J Immunol. 2005 Mar;35(3):890-900.

7.

Gamma delta T cell responses associated with the development of tuberculosis in health care workers.

Ordway DJ, Pinto L, Costa L, Martins M, Leandro C, Viveiros M, Amaral L, Arroz MJ, Ventura FA, Dockrell HM.

FEMS Immunol Med Microbiol. 2005 Mar 1;43(3):339-50.

8.

The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.

de Lisle GW, Wards BJ, Buddle BM, Collins DM.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):73-9. Epub 2004 Dec 28.

PMID:
15687030
9.

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff TH, Franken KL, Andersen P, Doherty TM, Kaufmann SH, Grode L, Seiler P, Martin C, Gicquel B, Cole ST, Brodin P, Pym AS, Dalemans W, Cohen J, Lobet Y, Goonetilleke N, McShane H, Hill A, Parish T, Smith D, Stoker NG, Lowrie DB, Källenius G, Svenson S, Pawlowski A, Blake K, Marsh PD.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38. Epub 2005 Jan 20.

PMID:
15687025
10.

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, Jacobs WR Jr.

Infect Immun. 2005 Feb;73(2):1196-203.

11.
12.

Reduced local growth and spread but preserved pathogenicity of a DeltapurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection.

Brown N, Jacobs M, Parida SK, Botha T, Santos A, Fick L, Gicquel B, Jackson M, Quesniaux V, Ryffel B.

Infect Immun. 2005 Jan;73(1):666-70.

13.

Quantitative association tests of immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa.

Wiart A, Jepson A, Banya W, Bennett S, Whittle H, Martin NG, Hill AV.

Twin Res. 2004 Dec;7(6):578-88.

PMID:
15607008
14.

Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis.

Welsh MD, Cunningham RT, Corbett DM, Girvin RM, McNair J, Skuce RA, Bryson DG, Pollock JM.

Immunology. 2005 Jan;114(1):101-11.

15.

Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis.

Doherty TM, Olsen AW, Weischenfeldt J, Huygen K, D'Souza S, Kondratieva TK, Yeremeev VV, Apt AS, Raupach B, Grode L, Kaufmann S, Andersen P.

J Infect Dis. 2004 Dec 15;190(12):2146-53. Epub 2004 Nov 8.

16.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.

PMID:
15502839
17.

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, Reed SG, Orme IM.

Infect Immun. 2004 Nov;72(11):6622-32.

19.

Potential public health impact of new tuberculosis vaccines.

Ziv E, Daley CL, Blower S.

Emerg Infect Dis. 2004 Sep;10(9):1529-35. Review.

20.

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P.

Infect Immun. 2004 Oct;72(10):6148-50.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk